173 related articles for article (PubMed ID: 31232425)
1. Radiotherapy, Lymphopenia, and Host Immune Capacity in Glioblastoma: A Potentially Actionable Toxicity Associated With Reduced Efficacy of Radiotherapy.
Kleinberg L; Sloan L; Grossman S; Lim M
Neurosurgery; 2019 Oct; 85(4):441-453. PubMed ID: 31232425
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapy, lymphopenia and improving the outcome for glioblastoma: a narrative review.
Kut C; Kleinberg L
Chin Clin Oncol; 2023 Feb; 12(1):4. PubMed ID: 36922353
[TBL] [Abstract][Full Text] [Related]
3. Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation.
Koukourakis MI; Giatromanolaki A; Schiza S; Kakolyris S; Georgoulias V
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):107-14. PubMed ID: 9989521
[TBL] [Abstract][Full Text] [Related]
4. Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma.
Mendez JS; Govindan A; Leong J; Gao F; Huang J; Campian JL
J Neurooncol; 2016 Apr; 127(2):329-35. PubMed ID: 26725885
[TBL] [Abstract][Full Text] [Related]
5. Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era.
Byun HK; Kim N; Yoon HI; Kang SG; Kim SH; Cho J; Baek JG; Chang JH; Suh CO
Radiat Oncol; 2019 Mar; 14(1):51. PubMed ID: 30917849
[TBL] [Abstract][Full Text] [Related]
6. Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells.
Authier A; Farrand KJ; Broadley KW; Ancelet LR; Hunn MK; Stone S; McConnell MJ; Hermans IF
Int J Cancer; 2015 Jun; 136(11):2566-78. PubMed ID: 25363661
[TBL] [Abstract][Full Text] [Related]
7. Glioblastoma-derived mechanisms of systemic immunosuppression.
Waziri A
Neurosurg Clin N Am; 2010 Jan; 21(1):31-42. PubMed ID: 19944964
[TBL] [Abstract][Full Text] [Related]
8. New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors.
De Felice F; Musio D; Cassese R; Gravina GL; Tombolini V
Curr Cancer Drug Targets; 2017; 17(3):282-289. PubMed ID: 27528363
[TBL] [Abstract][Full Text] [Related]
9. Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial.
Kong L; Gao J; Hu J; Lu R; Yang J; Qiu X; Hu W; Lu JJ
Cancer Commun (Lond); 2019 Feb; 39(1):5. PubMed ID: 30786916
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3.
Ventero MP; Fuentes-Baile M; Quereda C; Perez-Valeciano E; Alenda C; Garcia-Morales P; Esposito D; Dorado P; Manuel Barbera V; Saceda M
PLoS One; 2019; 14(2):e0212581. PubMed ID: 30811476
[TBL] [Abstract][Full Text] [Related]
11. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
Minniti G; Amelio D; Amichetti M; Salvati M; Muni R; Bozzao A; Lanzetta G; Scarpino S; Arcella A; Enrici RM
Radiother Oncol; 2010 Dec; 97(3):377-81. PubMed ID: 20855119
[TBL] [Abstract][Full Text] [Related]
12. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.
Chongsathidkiet P; Jackson C; Koyama S; Loebel F; Cui X; Farber SH; Woroniecka K; Elsamadicy AA; Dechant CA; Kemeny HR; Sanchez-Perez L; Cheema TA; Souders NC; Herndon JE; Coumans JV; Everitt JI; Nahed BV; Sampson JH; Gunn MD; Martuza RL; Dranoff G; Curry WT; Fecci PE
Nat Med; 2018 Sep; 24(9):1459-1468. PubMed ID: 30104766
[TBL] [Abstract][Full Text] [Related]
13. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.
Weiss T; Weller M; Guckenberger M; Sentman CL; Roth P
Cancer Res; 2018 Feb; 78(4):1031-1043. PubMed ID: 29222400
[TBL] [Abstract][Full Text] [Related]
14. Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment.
Ishikawa E; Yamamoto T; Sakamoto N; Nakai K; Akutsu H; Tsuboi K; Takano S; Matsumura A
Neurol Med Chir (Tokyo); 2010; 50(8):638-44. PubMed ID: 20805645
[TBL] [Abstract][Full Text] [Related]
15. Human cytomegalovirus-mediated immunomodulation: Effects on glioblastoma progression.
Foster H; Ulasov IV; Cobbs CS
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):273-276. PubMed ID: 28554666
[TBL] [Abstract][Full Text] [Related]
16. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
[TBL] [Abstract][Full Text] [Related]
17. From lymphopenia to restoration: IL-7 immunotherapy for lymphocyte recovery in glioblastoma.
Kim J; Choi H; Jeun SS; Ahn S
Cancer Lett; 2024 Apr; 588():216714. PubMed ID: 38369003
[TBL] [Abstract][Full Text] [Related]
18. MSI1 associates glioblastoma radioresistance via homologous recombination repair, tumor invasion and cancer stem-like cell properties.
Lin JC; Tsai JT; Chao TY; Ma HI; Chien CS; Liu WH
Radiother Oncol; 2018 Nov; 129(2):352-363. PubMed ID: 30322656
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of immunomodulation in human glioblastoma.
Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
[TBL] [Abstract][Full Text] [Related]
20. Apoptotic elimination of peripheral T lymphocytes in patients with primary intracranial tumors.
Morford LA; Dix AR; Brooks WH; Roszman TL
J Neurosurg; 1999 Dec; 91(6):935-46. PubMed ID: 10584838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
